Where Teva Pharmaceutical Indus Stands With Analysts

In the last three months, Teva Pharmaceutical Industries (TEVA) has received generally bullish ratings from analysts, with 3 out of 4 ratings being either bullish or somewhat bullish. The average analyst price target has increased by 5.49% to $22.50, with targets ranging from $20.00 to $25.00. Recent analyst actions include Truist Securities initiating coverage with a Buy rating and JP Morgan upgrading its rating to Overweight, reflecting a positive shift in sentiment despite Teva's challenges in revenue growth and net margin compared to industry peers.

Analysis

Analyst sentiment towards Teva Pharmaceutical Industries (TEVA) has been predominantly positive over the last three months, with three out of four published ratings being bullish and one somewhat bullish. This positive outlook is further supported by an increase in the average 12-month price target by 5.49% to $22.50, from a previous average of $21.33, with individual targets ranging from $20.00 to $25.00. Notably, recent analyst actions in May 2025 include Truist Securities initiating coverage with a 'Buy' rating and a $25.00 price target, JP Morgan upgrading its rating from 'Neutral' to 'Overweight' with a price target increase from $21.00 to $23.00, and B of A Securities raising its price target on a 'Buy' rating from $20.00 to $22.00. Teva, a leading global generic drug manufacturer, reported revenue growth of 1.89% as of March 31, 2025; however, this growth lags behind its industry peers in the Health Care sector. The company's financial profile presents a mixed picture: its net margin of 5.5% is below industry standards, indicating challenges in profitability and cost control, and its Return on Assets (ROA) of 0.55% also trails industry averages, suggesting inefficiencies in asset utilization. Furthermore, Teva's debt-to-equity ratio of 2.71 is higher than the industry average, signaling increased financial risk. Conversely, Teva's Return on Equity (ROE) of 3.68% surpasses industry benchmarks, indicating efficient use of shareholder equity.

Key Decisions for Investors

• Investors should note the recent positive analyst momentum, including upgrades and increased price targets, which may signal near-term upside potential for Teva Pharmaceutical Industries.
• Careful consideration of Teva's mixed financial fundamentals is warranted, particularly its modest revenue growth relative to peers, below-average net margin and ROA, and elevated debt-to-equity ratio, despite a strong ROE.
• Monitor Teva's progress in addressing its financial challenges, specifically improvements in revenue growth trajectory, cost management to enhance net margins, and strategies for debt reduction, to validate the sustainability of the current bullish analyst outlook.